Furthermore, dihydroartemisinin damages heme metabolism in osimertinib-resistant EGFR mutant NSCLC (PC9-OR3, PC9-OR5, PC9-GR1-AZD2, and PC9-GR4-AZD1) cells, thereby inhibits cell proliferation with relatively low toxicity [123]. Here, EGFR is linked to non-small cell lung carcinoma.